ACC panel unleashes Vytorin whirlwind

If Merck and Schering-Plough really expected their Enhance presentation to turn the tide on Vytorin and Zetia, then they were sorely disappointed this weekend. At the American College of Cardiology confab, a panel of heart docs said the Enhance data offered little redemption for Zetia and its cousin Vytorin, a Zetia-and-Zocor combo med. The media coverage today is extensive. Here's a representative sampling:

  • Enhance data showed no benefit to treatment with Vytorin, the study's lead investigator said. "Zilch." John Kastelein told the WSJ Health Blog that Enhance was a "trial out of hell" and that he'll never conduct research in the same way again.
  • Before a panel of experts spoke to the ACC, they reached consensus on the two meds and issued a press release urging docs to back away from the drugs. The cardiologists recommended a return to tried-and-true cholesterol treatments such as Merck's Zocor--which recently went generic--Pfizer's Lipitor, and AstraZeneca's Crestor. These meds have been shown to not only lower bad cholesterol, but also have effects on heart disease, the docs said.
  • Wall Street analysts, stunned by the negativity of the ACC discussion on Vytorin and Zetia, lowered their sales estimates for the meds and downgraded Schering-Plough's stock.
  • The New England Journal of Medicine said Vytorin and Zetia may not work and should only be used as last-resort alternatives if other cholesterol treatments--diet, exercise, statins, niacin, fibrates, and resins included--either fail to work or can't be tolerated by a patient. There's no evidence that the drugs help patients, a Yale cardiologist told the ACC meeting, and may even be harmful.
  • Researchers found that the U.S. spent billions more on Vytorin and Zetia than Canada did, positing that the lack of DTC advertising in Canada may account for the difference.
  • Schering-Plough stock dropped 17 percent before the bell this morning and Merck fell 10 percent.
  • Amid the firestorm of bad publicity, Merck and Schering-Plough stood behind their products, citing various reasons why Enhance failed to prove Vytorin's superiority; for one thing, patients in the study had been treated already with statins, and so it would be more difficult to show a benefit. The companies said the meds remain good first-line treatment options for cholesterol.

No doubt the data will continue to get sifted and hashed over in coming days. But until outcomes data for Vytorin are available--now unlikely until at least 2012--any new, concrete info will be hard to come by.

- here's the release from Merck
- read the Associated Press story on the retreat to older meds
- see Kastelein's comments in the Health Blog
- check out what analysts are telling the WSJ
- find the NYT's coverage of the meeting
- read New Scientist's story about Canadian ezetimibe spending
- see the stock performance news at MarketWatch

Related Articles:
Companies saw Vytorin threat in 2005. Report
Congress: Were Enhance results secret? Report
FDA to review Enhance study. Report
Congress promises Vytorin hearings. Report
Merck, Schering defend embattled Vytorin. Report
Merck, Schering's Vytorin fails trial. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.